Clinical practice guidelines for the management of adult diffuse gliomas
Tao Jiang,Do-Hyun Nam,Zvi Ram,Wai-sang Poon,Jiguang Wang,Damdindorj Boldbaatar,Ying Mao,Wenbin Ma,Qing Mao,Yongping You,Chuanlu Jiang,Xuejun Yang,Chunsheng Kang,Xiaoguang Qiu,Wenbin Li,Shaowu Li,Ling Chen,Xuejun Li,Zhixiong Liu,Weimin Wang,Hongmin Bai,Yu Yao,Shouwei Li,Anhua Wu,Ke Sai,Guilin Li,Kun Yao,Xinting Wei,Xianzhi Liu,Zhiwen Zhang,Yiwu Dai,Shengqing Lv,Liang Wang,Zhixiong Lin,Jun Dong,Guozheng Xu,Xiaodong Ma,Wei Zhang,Chuanbao Zhang,Baoshi Chen,Gan You,Yongzhi Wang,Yinyan Wang,Zhaoshi Bao,Pei Yang,Xing Fan,Xing Liu,Zheng Zhao,Zheng Wang,Yiming Li,Zhiliang Wang,Guanzhang Li,Shengyu Fang,Lianwang Li,Yanwei Liu,Shuai Liu,Xia Shan,Yuqing Liu,Ruichao Chai,Huimin Hu,Jing Chen,Wei Yan,Jinquan Cai,Hongjun Wang,Lingchao Chen,Yuan Yang,Yu Wang,Lei Han,Qixue Wang,Chinese Glioma Cooperative Group,Society for Neuro‐Oncology of China,Chinese Brain Cancer Association,Chinese Glioma Genome Atlas,Asian Glioma Genome Atlas network
DOI: https://doi.org/10.1016/j.canlet.2020.10.050
IF: 9.756
2021-02-01
Cancer Letters
Abstract:To follow the revision of the fourth edition of WHO classification and the recent progress on the management of diffuse gliomas, the joint guideline committee of Chinese Glioma Cooperative Group (CGCG), Society for Neuro-Oncology of China (SNO-China) and Chinese Brain Cancer Association (CBCA) updated the clinical practice guideline. It provides recommendations for diagnostic and management decisions, and for limiting unnecessary treatments and cost. The recommendations focus on molecular and pathological diagnostics, and the main treatment modalities of surgery, radiotherapy, and chemotherapy. In this guideline, we also integrated the results of some clinical trials of immune therapies and target therapies, which we think are ongoing future directions. The guideline should serve as an application for all professionals involved in the management of patients with adult diffuse glioma and also a source of knowledge for insurance companies and other institutions involved in the cost regulation of cancer care in China and other countries.
oncology